Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
It is used for recovery from injuries, improving gut health, and healing muscles, ligaments, and tendons
Likely to reach market before retatrutide, which is still in Phase 3 trials
Its nearly two-year shortage ended in October, at which time the trade group Outsourcing Facilities Association sued the FDA
but lower doses led to more modest weight loss:Lower doses had a more favourable side effect profile, too:This triple agonism aims to relieve some of the side effects of GLP1s (nausea, muscle loss), and increase weight loss (so the dose can be lowered)Sources: New obesity drugs - nature.com/articles/d4158 Triple agonist Retatrutide phase 2 trial - nejm.org/doi/full/10.10 full article: openread.academy/en/paper/readi Breakdown of the article: The article discusses the development of new obesity drugs that aim to provide greater and healthier weight loss
